Alhelí Adán-Ladrón de Guevara

Alhelí Adán-Ladrón de Guevara

Auto-generated profile, based on publicly available information

Alhelí Adán-Ladrón de Guevara

Departamento de Bioquímica, Instituto Nacional de Cardiología, Ciudad de México, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JGJuan Carlos Gallardo-Pérez
Juan Carlos Gallardo-Pérez
AGAlhelí Adán-Ladrón de Guevara
Alhelí Adán-Ladrón de Guevara
MGMarco Antonio García-Amezcua
Marco Antonio García-Amezcua
DRDiana Xochiquetzal Robledo-Cadena
Diana Xochiquetzal Robledo-Cadena
SPSilvia Cecilia Pacheco-Velázquez
Silvia Cecilia Pacheco-Velázquez
SRSARA RODRIGUEZ-ENRIQUEZ
SARA RODRIGUEZ-ENRIQUEZ
Background: The major hurdles for successful cancer treatment are drug resistance and invasiveness developed by breast cancer stem cells (BCSC). Objective: As these two processes are highly energy-dependent, the identification of the main ATP supplier required for stem cell viability may result advantageous in the design of new therapeutic strategies to deter malignant carcinomas. Methods: The energy metabolism (glycolysis and oxidative phosphorylation, OxPhos) was systematically analyzed by assessing relevant protein contents, enzyme activities, and pathway fluxes in BCSC. Once identified as the main ATP supplier, selective energy inhibitors and canonical breast cancer drugs were used to block stem cell viability and metastatic properties. Results: OxPhos and glycolytic protein contents, as well as HK and LDH activities were several times higher in BCSC than in their parental line, MCF-7 cells. However, CS, GDH, COX activities, and both energy metabolism pathway fluxes were significantly lower (38-86%) in BCSC than in MCF-7 cells. OxPhos was the main ATP provider (>85%) in BCSC. Accordingly, oligomycin (a specific and potent canonical OxPhos inhibitor) and other non-canonical drugs with inhibitory effect on OxPhos (celecoxib, dimethylcelecoxib) significantly decreased BCSC viability, levels of epithelial-mesenchymal transition proteins, invasiveness, and induced ROS over-production, with IC50 values ranging from 1 to 20 μM in 24 h treatment. In contrast, glycolytic inhibitors (gossypol, iodoacetic acid, 3-bromopyruvate, 2-deoxyglucose) and canonical chemotherapeutic drugs (paclitaxel, doxorubicin, cisplatin) were much less effective against BCSC viability (IC50> 100 μM). Conclusion: These results indicated that the use of some NSAIDs may be a promising alternative therapeutic strategy to target BCSC.